E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/21/2015 in the Prospect News Convertibles Daily.

Morning Commentary: Whiting Petroleum weakens; Energy XXI down; United Tech mandatories in line

By Rebecca Melvin

New York, July 21 – U.S. convertibles saw ongoing weakness in the energy sector early Tuesday despite a bounce back in crude oil prices above $50 per barrel. Convertibles traders were also focused on earnings news.

Whiting Petroleum Corp.’s 1.25% convertibles due 2020 fell another couple of points to a 93 handle, according to Trace data, after dropping a couple of points in Monday. The bonds were recently above par. The common shares of the Denver-based oil and gas E&P company were last up 1% at $25.29.

Energy XXI Ltd.’s 3% convertibles due 2018 took another leg lower to the 12.5 to 13 context after trading at 14 to 15 in recent sessions. The common shares of the Hamilton, Bermuda-based independent oil and natural gas E&P company popped early Tuesday by about 25 cents, or 14.6%, to about $1.90.

The downturn in the bonds of natural resources companies, such as oil and coal names, has been an ongoing theme in both the convertibles and high-yield straight bond markets.

West Texas Intermediate crude for August delivery was back above $50.00 per barrel, after closing down on Monday at $49.96 per barrel.

Elsewhere, United Technologies Corp.’s mandatory convertibles, which mature Aug. 1, were moving lower in tandem with the common shares, which were down about 7% at late morning, after the Hartford, Conn.-based building and aerospace technology company cut full-year guidance, citing weaker sales and headwinds caused by the strong dollar.

The UTX mandatories were down $3.77, or 6.7%, at $52.77 at 10:30 a.m. ET.

Exelixis Inc. continued to trade actively at steady pricing the day after news of a positive late-stage drug study that propelled the 4.25% convertibles up more than 30 points. The common shares of the South San Francisco, Calif.-based biotechnology company were lower in the early going Tuesday.

Traders were also eyeing Illumina Inc., which was slated to report quarterly results after the market close.

The Illumina 0% convertible notes due 2019 were last unchanged at 122, according to Trace data, and the Illumina 0.5% convertible notes due 2021 were a little higher, trading at 130.78 from 128 to 130 on Monday.

The common shares of the San Diego-based developer of genetic research tools were down $7.00, or 3%, at $232.88.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.